Wow, can't believe how fast time flies, it's been over 7 months since some members started experimenting with this. So what's the consensus so far? Is this thing a potential game changer or what?
I also suffer from chronic tellogen effluvium since I was 18 (I can confim because lost hair regrows some 6 months later)
so it's helpful to stop the shedding
609
Topical Sandalore, a specific OR2AT4-stimulating odorant, ameliorates
female telogen effluvium: Randomized, double-blinded, placebo-controlled
clinical trial
M Bertolini1
, F Jimenez2
, E Lopez2
, M Alam3
, C Ward1
, J Che ́ret4
, G Westgate5
, F Rinaldi6
and R Paus4,7 1 Monasterium Laboratory, Skin and Hair Research Solutions, Muenster,
Germany, 2 Mediteknia Clinic and Monasterium Clinical Hair Trial Unit, Gran Canaria,
Spain, 3 Mediteknia Skin & Hair Lab, Gran Canaria, Spain, 4 University of Miami, Miami,
Florida, United States, 5 Gill Westgate Consultancy Ltd, Bedford, United Kingdom, 6
Giuliani S.p.A., Milan, Italy and 7 University of Manchester, Manchester, United Kingdom
Human hair follicles (HFs) express the olfactory receptor OR2AT4, whose specific stimulation
by the synthetic sandalwood-like odorant, Sandalore, prolongs anagen ex vivo. To study
whether this effect of Sandalore is clinically relevant, we conducted a randomized, double-
blinded, placebo-controlled, prospective clinical trial involving 60 female volunteers affected
by telogen effluvium with a defined, substantial degree of hair shedding. Patients were treated
topically with a solution containing either 1% Sandalore (verum) or natural sandalwood oil
(placebo), which has the same odor as Sandalore but does not stimulate OR2AT4, over a
period of 24 weeks. Sandalore 1% ameliorated clinical signs of telogen effluvium, namely it
reduced hair shedding, increased hair volume and increased the percentage of anagen HFs
over time significantly more than placebo, and showed a trend towards increasing the ratio of
terminal/vellus hairs. Hair shaft thickness and density were not affected. Most of the anti-hair
shedding effects were seen already after 8 weeks and maintained at week 24. Subjectively,
individuals in the treatment group were “more satisfied” than in the placebo group regarding
hair appearance and overall results. This clinical trial confirmed the anagen-maintaining ef-
fects of Sandalore seen ex vivo and provides the first evidence that a cosmetic odorant can
positively impact on human hair growth in vivo, encouraging the use of topical “olfacto-
therapy” with Sandalore as adjunct therapy of hair disorders characterized by excessive hair
shedding.